Study type: Human research · Status: Verified against declared source

The Human Cathelicidin Antimicrobial Chemical sequence LL-37 as a Potential Treatment for Polymicrobial Infected Wounds.

Frontiers in immunology · 2013

Study scale: Prevalence of diabetes in the US (red) and the number of lower-limb amputations.

Product or molecular entity relationships

LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

LL-37 has broad-spectrum antimicrobial activity against both Gram-negative and Gram-positive bacteria (Durr et al., 2006) including drug-resistant strains (Saiman et al., 2001; Zaiou et al., 2003; Schittek et al., 2008).

Methods

Methods for screening new molecules for anti-biofilm activity in an in vitro model of an infected wound are available.

Scale or participants

Prevalence of diabetes in the US (red) and the number of lower-limb amputations.

Key findings

Diabetic patients often have ulcers on their lower-limbs that are infected by multiple biofilm-forming genera of bacteria, and the elimination of the biofilm has proven highly successful in resolving such wounds in patients.

Limitations and uncertainty

In order to begin to understand how LL-37 interacts with biofilms, bacteria, and host cells, it is important to consider its features and secondary structure.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.